Systemic chemotherapy - before or after radical surgery in treatment of patients with advanced ovarian

被引:0
作者
Zamurovic, M. [1 ]
Jurisic, A. [1 ]
Andjelic, S. [1 ]
机构
[1] Gynecol & Obstet Clin Narodni Front, Belgrade 11000, Serbia
关键词
Ovarian carcinoma; Radical surgery; Chemotherapy; Overall survival; Progression-free survival; QUALITY-OF-LIFE; CYTOREDUCTIVE SURGERY; CANCER; SURVIVAL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of investigation The aim of the study was to analyze whether application of systemic chemotherapy prior to radical surgery in patients with advanced ovarian carcinoma influences the length of the progression-free period and overall survival rate Methods This study analyzes two groups of patients in the period 2006-2009 The first group received systemic chemotherapy prior to radical surgery The second group first had radical surgery after which systemic chemotherapy was administered The therapeutic response to systemic chemotherapy was analyzed as well as progression-free survival and overall survival which was calculated according to the Kaplan-Meier method and compared using the log rank test Results. Statistical analysis showed that patients who were administered systemic chemotherapy prior to radical surgery have significantly better progression-free survival as well as overall survival Progression-free survival in patients who were first treated with systemic chemotherapy after which radical surgery followed was equal to 28 months and was significantly longer (p = 0 001) than progression-free survival in patients who were first subjected to radical surgery, it equaled 13 months. while the overall survival equaled 43 and 36 months. respectively Conclusion Application of systemic chemotherapy prior to radical surgery has a significant influence on the length of the progression-free period and on the length of overall survival of patients affected by advanced ovarian cancer
引用
收藏
页码:564 / 566
页数:3
相关论文
共 14 条
[1]   Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy [J].
Brun, Jean-Luc ;
Rouzier, Roman ;
Selle, Frederic ;
Houry, Sidney ;
Uzan, Serge ;
Darai, Emile .
BMC CANCER, 2009, 9
[2]   Cytoreductive surgery for recurrent ovarian cancer [J].
Hauspy, Jan ;
Covens, Allan .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2007, 19 (01) :15-21
[3]   Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer -: a study by the AGO OVAR Germany [J].
Hilpert, F. ;
du Bois, A. ;
Greimel, E. R. ;
Hedderich, J. ;
Krause, G. ;
Venhoff, L. ;
Loibl, S. ;
Pfisterer, J. .
ANNALS OF ONCOLOGY, 2007, 18 (02) :282-287
[4]   Does Neoadjuvant Chemotherapy Increase Optimal Cytoreduction Rate in Advanced Ovarian Cancer? Meta-Analysis of 21 Studies [J].
Kang, Sokbom ;
Nam, Byung-Ho .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (08) :2315-2320
[5]  
KEHOE S, 2009, CLIN EVID 0116
[6]   Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments [J].
Kyrgiou, Maria ;
Salanti, Georgia ;
Pavlidis, Nicholas ;
Paraskevaidis, Evangelos ;
Ioannidis, John P. A. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (22) :1655-1663
[7]   Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy [J].
Matsumoto, Aya ;
Higuchi, Toshihiro ;
Yura, Shigeo ;
Mandai, Masaki ;
Kariya, Masatoshi ;
Takakura, Kenji ;
Fujii, Shingo .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2006, 32 (06) :580-587
[8]  
Menczer J, 2008, EUR J GYNAECOL ONCOL, V29, P473
[9]  
Moretti R, 2007, EUR J GYNAECOL ONCOL, V28, P325
[10]   Treatment goals in ovarian cancer [J].
Ozols, RF .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 :3-11